Reported Saturday, Sutro Biopharma Reveals Updated Data From Phase 1b Study Of Luvelta In Combination With Bevacizumab At ESMO 2024
Portfolio Pulse from Benzinga Newsdesk
Sutro Biopharma presented updated data from its Phase 1b study of Luvelta in combination with Bevacizumab at ESMO 2024. The combination showed a 56% objective response rate in late-stage ovarian cancer patients, with no new safety signals. The recommended phase 2 dose has been selected, and further expansion is ongoing.
September 16, 2024 | 8:53 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sutro Biopharma's Luvelta, in combination with Bevacizumab, achieved a 56% response rate in late-stage ovarian cancer patients in a Phase 1b study. The recommended phase 2 dose has been selected, and no new safety signals were observed.
The positive results from the Phase 1b study, including a high response rate and no new safety concerns, are likely to boost investor confidence in Sutro Biopharma. The selection of the recommended phase 2 dose and ongoing expansion indicate potential for further positive developments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100